Overview
Loiasis, caused by the filarial worm Loa loa, presents with diverse clinical manifestations including Calabar swellings and microfilaremia, differing significantly between endemic and nonendemic populations due to immunologic factors 1.Diagnosis
Clinical Presentation: Calabar swellings (rare in endemic populations), skin rashes, and ocular symptoms.
Laboratory Tests: Microscopic examination of blood for microfilariae (present in 90% of endemic patients 1).
Immunologic Markers: Decreased peripheral blood eosinophils, lower parasite-specific IgG, and reduced lymphocyte proliferation in endemic populations compared to nonendemic 1.Management
First-Line Treatment: Diethylcarbamazine (DEC) is commonly used but requires careful monitoring due to potential encephalopathy in loiasis 1.
Adjunctive Measures: Supportive care for symptoms, including pain management for Calabar swellings.
Avoid Certain Medications: Avoid treatments that may exacerbate encephalopathy risk, such as ivermectin, without careful evaluation 1.Special Populations
Immune Response Differences: Endemic populations show altered immune responses with lower eosinophil counts and IgG levels compared to nonendemic populations, impacting clinical presentation 1.
No Specific Guidance: Abstracts do not provide detailed management guidelines for pregnancy, pediatrics, or elderly patients 1.Key Recommendations
Differentiate clinical presentation based on endemic vs. nonendemic status, considering immunologic differences in diagnosis 1 (Evidence: Moderate).
Use DEC cautiously for treatment, monitoring for signs of encephalopathy, especially in endemic populations 1 (Evidence: Moderate).
Avoid ivermectin in loiasis patients without thorough risk assessment due to potential encephalopathy risk 1 (Evidence: Expert opinion).References
1 Klion AD, Massougbodji A, Sadeler BC, Ottesen EA, Nutman TB. Loiasis in endemic and nonendemic populations: immunologically mediated differences in clinical presentation. The Journal of infectious diseases 1991. link